STAT

Opinion: ‘Right-to-try’ laws provide little access to investigational drugs. We created a process that does

Compassion for people who are dying is ethically commendable. Duping them with ideologically driven #righttotry laws that provide no help is not.
President Trump signs the Right to Try Act into law in May 2018 in Washington.

‘Right-to-try’ legislation has been around at the state level in the U.S. since late 2014. It became a federal law one year ago when, with typical ballyhoo and hype, President Trump signed Senate Bill 204 into law on May 30, 2018.

As he signed the bill, the president said that “… countless American lives will ultimately be saved. We will be saving — I don’t even want to say thousands because I think it’s going to be much more — thousands and thousands, hundreds of thousands, we’re going to be saving tremendous numbers of lives.”

That hasn’t happened. The number of patients who have benefited from state or federal right-to-try laws can currently be measured

You’re reading a preview, subscribe to read more.

More from STAT

STAT1 min read
STAT+: Health Care Leaders Plot How To Expand Diversity In Clinical Trials
Experts gathered at the Milken Institute Global Conference this week to discussed potential strategies to expand diversity in clinical trials. Here are some of their big ideas.
STAT1 min read
STAT+: Senate Drug Shortage Bill Would Pay Hospitals Bonuses For Good Contracting Practices
A bipartisan Senate bill takes a new approach to persistent drug shortages: have Medicare pay bonuses to hospitals and physicians for contracting that ensures a steady supply.
STAT2 min readCrime & Violence
STAT+: Pharmalittle: We’re Reading About A Medicare Price-negotiation Ruling, Pharma’s Slipping Reputation, And More
A U.S. judge dealt a blow to two drugmakers challenging the authority for Medicare to negotiate the prices of prescription drugs.

Related Books & Audiobooks